Cancer/testis antigen 1 (87-100)

Cancer/testis antigen 1 (87-100) is a synthetic peptide fragment derived from the well-characterized cancer/testis antigen family, specifically encompassing amino acids 87 to 100 of the parent protein. These antigens are notable for their restricted expression profile, being primarily found in various tumor types and in germ cells of the testis, but absent from most normal somatic tissues. The unique expression pattern and immunogenic properties of this peptide make it a valuable tool in tumor immunology research, epitope mapping, and the study of antigen processing and presentation. Its defined sequence and structural features also provide a reliable model for investigating peptide-MHC interactions and T cell recognition events.

Immunological research: The peptide is widely employed as a model antigen in studies focused on cellular immune responses against tumor-associated antigens. Researchers utilize it to evaluate the activation and specificity of cytotoxic T lymphocytes (CTLs) in vitro, enabling the dissection of mechanisms underlying tumor immune surveillance and escape. The defined sequence allows for precise monitoring of T cell activation, cytokine secretion, and cytolytic activity, supporting the development of immunological assays and experimental platforms for cancer immunology.

Epitope mapping: As a well-characterized linear epitope, the peptide serves as a reference substrate for mapping T cell and antibody recognition sites within cancer/testis antigens. It enables the identification of minimal immunogenic sequences required for immune recognition, facilitating the design of optimized synthetic epitopes and the refinement of antigenic determinants. Such studies are crucial for understanding the structural basis of immune specificity and for guiding the rational design of immunotherapeutic agents or diagnostic reagents.

Antigen processing and presentation studies: The defined amino acid sequence of this peptide provides a model system for investigating the molecular pathways involved in antigen uptake, processing, and presentation by major histocompatibility complex (MHC) molecules. Researchers use it to analyze peptide binding affinities, stability of peptide-MHC complexes, and the efficiency of antigen presentation to T cells. These insights are essential for elucidating the determinants of immunogenicity and for optimizing peptide-based vaccine candidates.

Peptide-MHC binding assays: The synthetic nature and known sequence of the peptide make it suitable for use in in vitro binding assays, such as MHC stabilization or competitive binding studies. These assays are instrumental in quantifying the affinity of peptide-MHC interactions, characterizing allele-specific binding motifs, and screening for novel immunogenic peptides. Such applications contribute to the broader understanding of antigen presentation and the development of predictive algorithms for epitope selection.

Analytical and quality control studies: The peptide is also utilized as a reference standard or positive control in various analytical platforms, including mass spectrometry, high-performance liquid chromatography (HPLC), and immunoassays. Its defined composition and immunological relevance enable researchers to validate assay performance, calibrate instrumentation, and ensure the reproducibility of experimental results in peptide analysis and quantification.

1. Cationic cell-penetrating peptides are potent furin inhibitors

2. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function

3. Emerging applications of nanotechnology for diagnosis and therapy of disease: a review

4. P-selectin and Complement’s Role in a Neonatal Model of Germinal Matrix Hemorrhage-Induced Secondary Injury

5. Uncarboxylated osteocalcin decreases insulin-stimulated glucose uptake without affecting insulin signaling and regulators of mitochondrial biogenesis in myotubes